\-\ Texto\\:\\ \ \(0\)\
\-\ not\\ available\\.\ \(14\)\
\-\ the\\ pt\\ will\\ receive\\ combination\\ radiation\\ and\\ chemotherapy\\.\\ \\ the\\ overall\\ 5\\ year\\ survival\\ for\\ hodgkin\\'s\\ disease\\ with\\ treatment\\ is\\ 82\\%\\.\\ \\ pet\\ scans\\ are\\ a\\ useful\\ means\\ of\\ staging\\ and\\ followup\\ to\\ determine\\ relapse\\.\\ \\ this\\ pt\\ has\\ received\\ a\\ pet\\ scan\\ which\\ will\\ be\\ entered\\ and\\ updated\\ soon\\.\ \(0\)\
\-\ \\â\\€\\¢\\ increased\\ densities\\ in\\ the\\ anterior\\ and\\ posterior\\ mediastinum\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ prevascular\\ lymph\\ node\\,\\ 1\\.7cm\ \(0\)\
\-\ \\â\\€\\¢\\ enlarged\\ peritracheal\\ lymph\\ node\\,\\ 1\\.6cm\ \(0\)\
\-\ \\â\\€\\¢\\ moderate\\ pericardial\\ effusion\ \(0\)\
\-\ classical\\ hodgkin\\'s\\ lymphoma\\,\\ nodular\\ sclerosing\\ type\ \(0\)\
\-\ \\â\\€\\¢\\ thymic\\ tumors\ \(0\)\
\-\ \\â\\€\\¢\\ pericardial\\ tumors\ \(0\)\
\-\ \\â\\€\\¢\\ mediastinal\\ carcinoids\ \(0\)\
\-\ \\â\\€\\¢\\ cystic\\ mediastinal\\ lesions\ \(0\)\
\-\ \\â\\€\\¢\\ thoracic\\ fungal\\ infections\ \(0\)\
\-\ \\â\\€\\¢\\ other\\ causes\\ of\\ lymphadenopathy\ \(0\)\
\-\ 21\\ year\\ old\\ man\\ with\\ a\\ 2\\ month\\ history\\ of\\ abdominal\\ pain\\,\\ weight\\ loss\\,\\ fevers\\,\\ and\\ chills\\.\ \(1\)\
\-\ \\â\\€\\¢lymphomas\\ are\\ divided\\ into\\ hodgkin\\â\\€\\™s\\ and\\ non\\-hodgkin\\â\\€\\™s\\.\ \(0\)\
\-\ \\â\\€\\¢hodgkin\\â\\€\\™s\\ lymphoma\\ is\\ characterized\\ by\\ reed\\-sternberg\\ cells\\,\\ with\\ 4\\ subtypes\\.\ \(0\)\
\-\ \\â\\€\\¢in\\ the\\ thorax\\,\\ nodular\\ sclerosing\\ is\\ the\\ most\\ common\\ subtype\\ with\\ a\\ predilection\\ for\\ the\\ mediastinum\\.\ \(0\)\
\-\ \\â\\€\\¢nodular\\ sclerosing\\ accounts\\ for\\ \\>50\\%\\ of\\ hodgkin\\â\\€\\™s\\ lymphomas\\.\ \(0\)\
\-\ \\â\\€\\¢frequency\\ \\-\\ in\\ the\\ us\\,\\ 7400\\ estimated\\ new\\ cases\\ in\\ 2001\ \(0\)\
\-\ \\â\\€\\¢bimodal\\ distribution\\ \\-\\ 15\\-40\\ years\\ old\\,\\ \\>55\\ years\\ old\ \(0\)\
\-\ \\â\\€\\¢treatment\\ consists\\ of\\ radiation\\ and\\/or\\ chemotherapy\ \(0\)\
\-\ \\â\\€\\¢survival\\ rates\\,\\ 1yr\\-93\\%\\,\\ 5yr\\-82\\%\\,\\ 10yr\\-72\\%\\,\\ 15yr\\-63\\%\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ hodgkin\\:\\ 0\\.4408217801842038\ \(0\)\
\-\ sclerosing\\:\\ 0\\.22730772284315356\ \(0\)\
\-\ lymphomas\\:\\ 0\\.18706557315651035\ \(0\)\
\-\ nodular\\:\\ 0\\.1718393421537291\ \(0\)\
\-\ 82\\:\\ 0\\.1464778544012561\ \(0\)\
\-\ pericardial\\:\\ 0\\.1407589561222581\ \(0\)\
\-\ survival\\:\\ 0\\.14039609277447865\ \(0\)\
\-\ pet\\:\\ 0\\.13323139051918165\ \(0\)\
\-\ mediastinum\\:\\ 0\\.12876945149907504\ \(0\)\
\-\ node\\:\\ 0\\.12364693791843563\ \(0\)\
\-\ mediastinal\\:\\ 0\\.11616127855005551\ \(0\)\
\-\ peritracheal\\:\\ 0\\.11502843906095461\ \(0\)\
\-\ lymph\\:\\ 0\\.11186375216939685\ \(0\)\
\-\ 7400\\:\\ 0\\.10991581444654075\ \(0\)\
\-\ tumors\\:\\ 0\\.10579859809513052\ \(0\)\
\-\ and\\:\\ 0\\.10404120117077428\ \(0\)\
\-\ pt\\:\\ 0\\.10352826750587829\ \(0\)\
\-\ carcinoids\\:\\ 0\\.1034746691901094\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.1021471957171896\ \(0\)\
\-\ the\\:\\ 0\\.10046561591150738\ \(0\)\
\-\ prevascular\\:\\ 0\\.09923199527164835\ \(0\)\
\-\ enlarged\\:\\ 0\\.0980684726273188\ \(0\)\
\-\ entered\\:\\ 0\\.09606310032534497\ \(0\)\
\-\ radiation\\:\\ 0\\.09533086077130973\ \(0\)\
\-\ relapse\\:\\ 0\\.0947345796833275\ \(0\)\
\-\ will\\:\\ 0\\.09258949651736433\ \(0\)\
\-\ updated\\:\\ 0\\.09049190576486645\ \(0\)\
\-\ years\\:\\ 0\\.08818173274382081\ \(0\)\
\-\ classical\\:\\ 0\\.08732301081856307\ \(0\)\
\-\ lymphoma\\:\\ 0\\.08567508726651672\ \(0\)\
\-\ subtypes\\:\\ 0\\.08479269707147327\ \(0\)\
\-\ subtype\\:\\ 0\\.08479269707147327\ \(0\)\
\-\ predilection\\:\\ 0\\.08318080981248228\ \(0\)\
\-\ means\\:\\ 0\\.0804684093807866\ \(0\)\
\-\ thymic\\:\\ 0\\.0804684093807866\ \(0\)\
\-\ divided\\:\\ 0\\.08006808103382704\ \(0\)\
\-\ accounts\\:\\ 0\\.08006808103382704\ \(0\)\
\-\ soon\\:\\ 0\\.0796800724570594\ \(0\)\
\-\ receive\\:\\ 0\\.07576924094771785\ \(0\)\
\-\ rates\\:\\ 0\\.07495545641941315\ \(0\)\
\-\ estimated\\:\\ 0\\.07469546197556017\ \(0\)\
\-\ staging\\:\\ 0\\.07347029669736731\ \(0\)\
\-\ thorax\\:\\ 0\\.07278854776072236\ \(0\)\
\-\ densities\\:\\ 0\\.07193335339622353\ \(0\)\
\-\ in\\:\\ 0\\.07157335109755437\ \(0\)\
\-\ consists\\:\\ 0\\.07152656702925679\ \(0\)\
\-\ of\\:\\ 0\\.07037990004489134\ \(0\)\
\-\ useful\\:\\ 0\\.06867292059754009\ \(0\)\
\-\ treatment\\:\\ 0\\.06852619140872958\ \(0\)\
\-\ 2001\\:\\ 0\\.06789910213688877\ \(0\)\
\-\ determine\\:\\ 0\\.06688982092064442\ \(0\)\
\-\ combination\\:\\ 0\\.06675201316876103\ \(0\)\
\-\ overall\\:\\ 0\\.06608469959006172\ \(0\)\
\-\ characterized\\:\\ 0\\.06608469959006172\ \(0\)\
\-\ chills\\:\\ 0\\.06545093385158583\ \(0\)\
\-\ for\\:\\ 0\\.06540242218262676\ \(0\)\
\-\ fungal\\:\\ 0\\.06438472574953752\ \(0\)\
\-\ old\\:\\ 0\\.06386333392178489\ \(0\)\
\-\ followup\\:\\ 0\\.06350720418347533\ \(0\)\
\-\ infections\\:\\ 0\\.06350720418347533\ \(0\)\
\-\ fevers\\:\\ 0\\.06350720418347533\ \(0\)\
\-\ scans\\:\\ 0\\.06258790202026325\ \(0\)\
\-\ received\\:\\ 0\\.06258790202026325\ \(0\)\
\-\ 55\\:\\ 0\\.061823468959217816\ \(0\)\
\-\ distribution\\:\\ 0\\.061015480470449024\ \(0\)\
\-\ is\\:\\ 0\\.05909386732347573\ \(0\)\
\-\ lymphadenopathy\\:\\ 0\\.05814973141386252\ \(0\)\
\-\ 21\\:\\ 0\\.05747527740584936\ \(0\)\
\-\ us\\:\\ 0\\.05721528296199637\ \(0\)\
\-\ with\\:\\ 0\\.05633756161471805\ \(0\)\
\-\ cells\\:\\ 0\\.05541946447717499\ \(0\)\
\-\ are\\:\\ 0\\.05458676594691009\ \(0\)\
\-\ causes\\:\\ 0\\.054350240882158014\ \(0\)\
\-\ moderate\\:\\ 0\\.05399645019284347\ \(0\)\
\-\ thoracic\\:\\ 0\\.053749685296166604\ \(0\)\
\-\ effusion\\:\\ 0\\.053412131729500184\ \(0\)\
\-\ 50\\:\\ 0\\.05023266739130524\ \(0\)\
\-\ weight\\:\\ 0\\.050158928679471984\ \(0\)\
\-\ new\\:\\ 0\\.04976089815188795\ \(0\)\
\-\ available\\:\\ 0\\.04880103287265272\ \(0\)\
\-\ cases\\:\\ 0\\.04837906121991297\ \(0\)\
\-\ type\\:\\ 0\\.048252014464634174\ \(0\)\
\-\ year\\:\\ 0\\.044333551570973156\ \(0\)\
\-\ loss\\:\\ 0\\.04382113878686525\ \(0\)\
\-\ month\\:\\ 0\\.04375459887631333\ \(0\)\
\-\ cystic\\:\\ 0\\.04331975289545661\ \(0\)\
\-\ scan\\:\\ 0\\.04267404981873751\ \(0\)\
\-\ lesions\\:\\ 0\\.04130903339498049\ \(0\)\
\-\ common\\:\\ 0\\.04079138217692267\ \(0\)\
\-\ anterior\\:\\ 0\\.040160360047408764\ \(0\)\
\-\ abdominal\\:\\ 0\\.03933929983275304\ \(0\)\
\-\ increased\\:\\ 0\\.03889521115417068\ \(0\)\
\-\ into\\:\\ 0\\.03823565608458778\ \(0\)\
\-\ man\\:\\ 0\\.03807954590637731\ \(0\)\
\-\ most\\:\\ 0\\.03743347943794049\ \(0\)\
\-\ other\\:\\ 0\\.03735333541524364\ \(0\)\
\-\ posterior\\:\\ 0\\.03719455954456379\ \(0\)\
\-\ has\\:\\ 0\\.032854588399458554\ \(0\)\
\-\ which\\:\\ 0\\.03270635117373007\ \(0\)\
\-\ by\\:\\ 0\\.030544776083851245\ \(0\)\
\-\ disease\\:\\ 0\\.03019279506587776\ \(0\)\
\-\ be\\:\\ 0\\.029178290811745115\ \(0\)\
\-\ not\\:\\ 0\\.028395440773100265\ \(0\)\
\-\ history\\:\\ 0\\.027480638054299428\ \(0\)\
\-\ pain\\:\\ 0\\.025738464924023836\ \(0\)\
\-\ this\\:\\ 0\\.02471573641175758\ \(0\)\
\-\ to\\:\\ 0\\.01798184437516146\ \(0\)\
